<DOC>
	<DOCNO>NCT00000136</DOCNO>
	<brief_summary>To evaluate relative safety efficacy ganciclovir foscarnet initial treatment patient cytomegalovirus ( CMV ) retinitis .</brief_summary>
	<brief_title>Studies Ocular Complications AIDS ( SOCA ) -- Foscarnet-Ganciclovir CMV Retinitis Trial ( FGCRT )</brief_title>
	<detailed_description>CMV retinitis common intraocular infection patient AIDS estimate affect 35 40 percent patient AIDS . Untreated CMV retinitis progressive disorder , end result total retinal destruction blindness . The first two drug approve United States Food Drug Administration ( FDA ) treatment CMV retinitis ganciclovir ( Cytovene ) foscarnet ( Foscavir ) . At time trial , ganciclovir foscarnet available intravenous formulation . Both drug give similar two-step fashion : initial 2-week course high-dose therapy ( induction ) control infection follow long-term low dose therapy prevent relapse ( maintenance ) . The FGCRT compare foscarnet ganciclovir initial therapy CMV retinitis . The FGCRT multicenter , randomize , control clinical trial compare foscarnet ganciclovir initial therapy CMV retinitis . Patients previously untreated CMV retinitis randomize therapy either intravenous ganciclovir intravenous foscarnet . The outcome measure trial survival , retinitis progression , loss visual function ( visual acuity visual field ) , morbidity .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Foscarnet</mesh_term>
	<mesh_term>Phosphonoacetic Acid</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Inclusion criterion : CMV retinitis one eye At least 1/4 disk one CMV lesion photographable Diagnosis AIDS define Center Disease Control criterion document HIV infection Age 13 great Visual acuity ≥ 3/200 least one eye diagnose CMV retinitis Absolute neutrophil count ≥ 1,000 cells/µl Platelet ≥ 25,000 cells/µl Serum creatinine ≥ 2.0 mg/dl Karnofsky score ≥ 60 Informed consent Exclusion criterion : Previous treatment CMV retinitis Treatment antiCMV therapy extraocular CMV infection currently past 28 day Known suspected allergy study drug Pregnant Lactating</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>